The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?
Open accessAbstract
Coronavirus disease 2019 (COVID‐19) is often associated with interstitial pneumonia. However, there is insufficient knowledge on the presence of autoimmune serological markers in patients with COVID‐19. We analyzed the presence and role of autoantibodies in patients with COVID‐19‐associated pneumonia. We prospectively studied 33 consecutive patients with COVID‐19, 31 (94%) of whom had interstitial pneumonia, and 25 age‐matched and sex‐matched patients with fever and/or pneumonia with etiologies other than COVID‐19 as the pathological control group. All patients were tested for the presence of antinuclear antibodies (ANAs), anti‐antiphospholipid antibodies, and anti‐cytoplasmic neutrophil antibodies (ANCAs). Clinical, biochemical, and radiological parameters were also collected. Fifteen of 33 patients (45%) tested positive for at least one autoantibody, including 11 who tested positive for ANAs (33%), 8 who tested positive for anti‐cardiolipin antibodies (immunoglobulin (Ig)G and/or IgM; 24%), and 3 who tested positive for anti‐β2‐glycoprotein antibodies (IgG and/or IgM; 9%). ANCA reactivity was not detected in any patient. Patients that tested positive for auto‐antibodies had a significantly more severe prognosis than other patients did: 6 of 15 patients (40%) with auto‐antibodies died due to COVID‐19 complications during hospitalization, whereas only 1 of 18 patients (5.5%) who did not have auto‐antibodies died (P = 0.03). Patients with poor prognosis (death due to COVID‐19 complications) had a significantly higher respiratory rate at admission (23 breaths per minute vs. 17 breaths per minute;P = 0.03) and a higher frequency of auto‐antibodies (86% vs. 27%;P = 0.008). In conclusion, auto‐antibodies are frequently detected in patients with COVID‐19 possibly reflecting a pathogenetic role of immune dysregulation. However, given the small number of patients, the association of auto‐antibodies with an unfavorable prognosis requires further multicenter studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Weekly, C., & The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) · China CDC Weekly · doi:10.46234/ccdcw2020.032 · Cited by 2,889
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Postmortem Examination of Patients With COVID-19
Schaller, T., Hirschbühl, K., Burkhardt, K., Braun, G., Trepel, M., Märkl, B., & Claus, R. (2020) · JAMA · doi:10.1001/jama.2020.8907 · Cited by 557 · cited 3×
“7 Hospitalization duration (days) 19 (3-28) 17 (5-19) 0.”
Cited by
COVID-19 and autoimmune diseases
Liu, Y., Sawalha, A. H., & Lu, Q. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000776 · Cited by 476
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Solomatina, L., & Chereshnev, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 281
Metadata
- Authors
- Pascolini, S., Vannini, A., Deleonardi, G., Ciordinik, M., Sensoli, A., Carletti, I., Veronesi, L., Ricci, C., Pronesti, A., Mazzanti, L., Grondona, A., Silvestri, T., Zanuso, S., Mazzolini, M., Lalanne, C., Quarneti, C., Fusconi, M., Giostra, F., Granito, A., Muratori, L., Lenzi, M., & Muratori, P.
- Venue
- Clinical and Translational Science
- Publisher
- Wiley
- Published
- 2021-01-20
- Volume
- 14
- Issue
- 2
- Pages
- 502-508
- ISSN
- 1752-8054 (ISSN-L)
- 1752-8062
- OpenAlex
- W3088728509
- Cited by
- 187
- References
- 5
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.